Clinical trial
LMBA02 Protocol for Patients With a Burkitt Lymphoma
NCT00180882 · Gustave Roussy, Cancer Campus, Grand Paris, Other · Unknown status
Key facts
| NCT number | NCT00180882 |
|---|---|
| Title | LMBA02 Protocol for Patients With a Burkitt Lymphoma |
| Lead sponsor | Gustave Roussy, Cancer Campus, Grand Paris, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Burkitt Lymphoma |
| Intervention type | Drug |
| Interventions | rituximab |
| Enrollment | 260 |
| Start date | Oct 1, 2004 |
| First posted | Sep 16, 2005 |
| Last update posted | Sep 11, 2006 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: